News and Events

Mar 2, 2018

Maryland Technology Development Corporation (TEDCO) and the National Cancer Institute (NCI) Technology Transfer Center (TTC) entered into a Partnership Intermediary Agreement to support their mutual interests: facilitate the development and licensing of NCI technologies and support collaborative opportunities with companies and Maryland educational institutions that commercialize products for public benefit.

Feb 9, 2018
Looking to work with the National Institutes of Health (NIH), the world’s largest biomedical research institution? The NIH Office of Technology Transfer has updated its "Business Opportunities at the NIH" guide for companies seeking new discoveries for commercialization, research & clinical collaboration opportunities or even funding. This general guide includes a brief overviews of the NIH, the research conducted by its 27 institutes and their technology transfer programs, along with where to follow-up concerning:
Dec 7, 2017


Chemotherapy is one of the most important treatments for colorectal cancer, especially those at late stages. Camptothecin (CPT) has demonstrated antitumor activity, but failed in clinical trials due to the low solubility and adverse side effects. In other words, CPT does not circulate well in the blood and is toxic to the body. In addition, these drugs do not target cancer cells well because of their low solubility.

Dec 6, 2017

The Technology Transfer Center (TTC) at the National Cancer Institute (NCI) is offering an exclusive Start-Up Evaluation Option License, called Start-Up 2.0, to qualified companies for term limited evaluation of certain early-stage vaccine, therapeutic, device, and diagnostic technologies stemming from the Intramural program at NCI and certain other Institutes serviced by TTC.

Nov 21, 2017

Obese women, particularly those who have gestational diabetes (high blood sugar during pregnancy) tend to have large babies, according to researchers at Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health. Their study findings were recently published in in the journal, JAMA Pediatrics.

Nov 9, 2017

Join federal technology transfer and regional business professionals on November 14-15, 2017 at The Universities at Shady Grove in Rockville, Maryland. Focus on day one of this Mid-Atlantic Regional Meeting is on "Challenges in the Adoption of Research Outcomes." Industry Partnering Day follows, with presentations, exhibition tables, and award presentations. Online and on-site registration is available.

Nov 3, 2017

Results from a large clinical trial in Liberia showed that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses that last for at least one year. One of the two vaccine candidate was co-developed by National Institute of Allergy and Infectious Diseases (NIAID)'s Vaccine Research Center (VRC) and GlaxoSmithKline (GSK).

Nov 2, 2017

The National Institutes of Health (NIH) announced $20 million in funding from the Stimulating Peripheral Activity to Relieve Conditions (SPARC) awards program.

Nov 1, 2017

The 2017 Deals of Distinction™ Award was presented to National Institutes of Health, (NIH) along with its corporate partners, AbbVie and Biogen, for a license agreement related to the development and launch of Zinbryta® for treatment of relapsing multiple sclerosis (MS)   The award, one of the most prestigious for technology transfer, was given to NIH and its partners at the Licensing Executives Society Annual Meeting in Chicago, Illinois.

Oct 20, 2017